about
A concise review of the toxicity and carcinogenicity of dimethylarsinic acidCorrelating in vitro data to in vivo findings for risk assessment.Tissue dosimetry, metabolism and excretion of pentavalent and trivalent monomethylated arsenic in mice after oral administrationTissue dosimetry, metabolism and excretion of pentavalent and trivalent dimethylated arsenic in mice after oral administration.Research approaches to address uncertainties in the risk assessment of arsenic in drinking water.Research toward the development of a biologically based dose response assessment for inorganic arsenic carcinogenicity: a progress report.Modeling the toxicokinetics of inhaled toluene in rats: influence of physical activity and feeding status.How can biologically-based modeling of arsenic kinetics and dynamics inform the risk assessment process? - A workshop review.Development and application of a human PBPK model for bromodichloromethane to investigate the impacts of multi-route exposure.Kinetic modeling of beta-chloroprene metabolism: II. The application of physiologically based modeling for cancer dose response analysis.Identifiability of PBPK models with applications to dimethylarsinic acid exposure.Dose and Effect Thresholds for Early Key Events in a PPARα-Mediated Mode of Action.Acute perchloroethylene exposure alters rat visual-evoked potentials in relation to brain concentrations.Acute toluene exposure and rat visual function in proportion to momentary brain concentration.A dosimetric analysis of the acute behavioral effects of inhaled toluene in rats.A physiologically based pharmacokinetic model for intravenous and ingested dimethylarsinic acid in mice.Extrapolating the acute behavioral effects of toluene from 1- to 24-h exposures in rats: roles of dose metric and metabolic and behavioral tolerance.The impact of variation in scaling factors on the estimation of internal dose metrics: a case study using bromodichloromethane (BDCM).Genome-wide analysis of DNA methylation and gene expression changes in the mouse lung following subchronic arsenate exposure.Tissue distribution and urinary excretion of inorganic arsenic and its methylated metabolites in C57BL6 mice following subchronic exposure to arsenate in drinking water.Concentration- and time-dependent genomic changes in the mouse urinary bladder following exposure to arsenate in drinking water for up to 12 weeks.Isolation of pathogenic Aspergillus species from commercially-prepared potting media.Inhibition of beta-glucuronidase in human urine by ascorbic acidIsolation of Sporothrix schenckii from potting soilBenzene: a case study in parent chemical and metabolite interactionsDose-, route-, and sex-dependent urinary excretion of phenol metabolites in B6C3F1 miceExtent and implications of interspecies differences in the intestinal hydrolysis of certain glucuronide conjugatesStrain-dependent disposition of inorganic arsenic in the mouseDose-dependent effects on tissue distribution and metabolism of dimethylarsinic acid in the mouse after intravenous administrationPharmacokinetic modeling of arsenite uptake and metabolism in hepatocytes--mechanistic insights and implications for further experimentsAn integrated pharmacokinetic and pharmacodynamic study of arsenite action 2. Heme oxygenase induction in miceTissue distribution and urinary excretion of inorganic arsenic and its methylated metabolites in mice following acute oral administration of arsenateDevelopment of a human physiologically based pharmacokinetic (PBPK) model for inorganic arsenic and its mono- and di-methylated metabolites
P50
Q29012941-68CA4B80-EBC2-444D-8BE1-06C7BAE5B85FQ30697409-D22A88D5-B8EE-4D43-990D-6384483655C8Q36628702-7C399692-29D0-472C-B837-754396790A43Q36628939-200A2F34-F4B0-4630-B43A-AC65F36969D7Q36767211-F9947980-00EE-4E03-AF26-4A1D10B9E954Q36820778-88F1490C-73CD-4E9E-96BE-1250867D40CDQ37078223-03427B96-66E5-494D-BA2F-E902A9334A10Q37237974-47FCF507-1CC2-4307-8205-63D3741297AAQ40230063-97E99D2C-F80A-4B90-882F-53DB7E25F04CQ40530198-88D79EA6-E41C-4693-9250-2F493BB34BBAQ40716052-32EE61FD-2616-4E35-B429-58B5C93C1F7AQ42700243-A30987E2-8FA2-40BF-8BA6-F74FD020C7A6Q46189317-72752773-F017-4CE9-8C4D-909D51DD4129Q48109156-72D041C7-BCF6-4A3C-BF57-25C039CF1876Q48146851-836BC4EB-DC95-4438-8429-3796D5DE2182Q48347710-B0D18FCC-C126-47C1-AE6F-E95C2F183F8FQ49124639-4F55277D-182A-4F2B-97C6-5AF75E4B3A55Q51533586-77C9AF2E-3B5B-482E-A5F4-4FBA4D73AFDFQ51550316-B8E1FAAD-5054-42A1-ABC9-5277CC83A920Q51688482-D6582955-5F3A-4419-A79E-C2C7396127E2Q52725197-CA4E13D8-AF2E-443B-9E81-A9CF0FF8F092Q53908647-0DFDC4A1-3014-4268-941B-E663D8416422Q68865468-6990797A-2352-4DEC-9625-430ECF60EAE6Q70655318-BD9ECE1C-48C3-48EB-BFEF-F0193804797CQ70924567-FAB22208-BBF9-4059-977B-783F79BB3C21Q72538923-1033708F-8655-4379-BF35-59817065F2AAQ72847665-114993E0-6468-43CE-8B2B-1C6C67064E68Q73082626-6325B62F-362F-4B4B-BFF9-20DF23BF1842Q73649336-97AD0B99-EE90-4818-9519-491B438E6613Q78566284-BF6F802A-AEDF-4AF7-9E68-A8205B9F8B02Q81119506-E75F4483-9FCB-4111-902B-264C6E6AE01AQ81385900-4DCF217A-579E-4F0E-AAEE-BCA0051D5CE3Q81455718-BBAC8509-A920-4910-B7F6-B656763F9BF4
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Elaina M. Kenyon
@ast
Elaina M. Kenyon
@en
Elaina M. Kenyon
@es
Elaina M. Kenyon
@nl
Elaina M. Kenyon
@sl
type
label
Elaina M. Kenyon
@ast
Elaina M. Kenyon
@en
Elaina M. Kenyon
@es
Elaina M. Kenyon
@nl
Elaina M. Kenyon
@sl
prefLabel
Elaina M. Kenyon
@ast
Elaina M. Kenyon
@en
Elaina M. Kenyon
@es
Elaina M. Kenyon
@nl
Elaina M. Kenyon
@sl
P106
P31
P496
0000-0001-8781-2391